المستخلص: |
Background: Chronic renal failure is associated with renal osteodystrophy, which is specific abnormalities of skeletal homeostasis, in which calcium and phosphorus level in patients blood be out of balance (hypocalcaemia and hyper phosphatemia), and if it not treated can result in bone problems. Renal osteodystrophy is treated by: 1. Calcium or native vitamin D supplementation 2. Restriction of dietary phosphate 3. Use of phosphate binder (calcium carbonate, calcium acetate, sevelamer,) 4. Cinacalet 5. Renal transplantation Objective: To evaluate the use of caco3 as phosphate binder in patients on dialysis in saheron hospital- Khartoum Method: Descriptive cross-sectional study was carried out. The study population was the patients on dialysis in saheron hospital. Patients were interviewed by questionnaire asking about their use of calcium carbonate and their knowledge about correct use .then compared to the standard guidelines about use of caco3 Results: Among a total of 78 surveyed patients, (94.9) % received caco3. while rest of participants (5.1) % did not take caco3. From total participants on dialysis after stop caco3 intake 37 (41) % show joint pain and backache .while 21 (33.3) % of them with no complain. From total participants on dialysis before stop of caco3 intake 61 % had no complain. 17.1 % of participants had joint pain and backache .also in same amount of 17.1 % of participants had joint pain .only 4.9 % had backache. Conclusions: calcium carbonate intake in dialyze patients required knowledgeable and patient aware with important to take it, to improve their quality of life.
|